Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

3518 ARTÍCULOS , VIENDO DEL 226 AL 240

A path to preventing cognitive impairment due to Alzheimer's disease: initiatives beginning in the USA

Reiman EM, Alexander RC, Langbaum JB, Aisen PS, Ashton N, Atri A, Barbarino P, Byrd GS, Feldman HH, Fowler NR, Ghisays V, Grill JD, Hassenstab J, Heaton GR, Herring WL, Jack CR Jr, Johnson SC, Karlawish J, Keach NL, Kivipelto M, Krumholz HM, Largent EA, MaGee-Rodgers T, McDade E, Mielke MM, Molina-Henry D, Petersen RC, Rabinovici GD, Ritchie C, Schindler SE, Sperling RA, Suárez-Calvet M, Vradenburg G, Weiner MW, Welsh-Bohmer KA, Zetterberg H, Zuendel MT, Mattke S, Cummings JL.

Lancet Neurol. 2026 Mar;25(3):268-278. doi: 10.1016/S1474-4422(25)00483-1.

Oxidative stress biomarkers and flavonoids in Alzheimer's disease: current clinical evidence and therapeutic perspectives

Zainuddin MS, Pamidi N, Azman AS, Bai Magalingam K, Bhuvanendran S.

Redox Rep. 2026 Dec 31;31(1):2677396. doi: 10.1080/13510002.2026.2677396. Epub 2026 May 26.

CTAD 2025: Key trends redefining therapeutic and diagnostic strategies in Alzheimer's disease

Yuan M, Zhou HY.

J Alzheimers Dis. 2026 May;111(1):56-62. doi: 10.1177/13872877261430764. Epub 2026 Mar 15.

Eligibility for lecanemab treatment in a French memory clinic setting

Vrillon A, Götze K, Dumurgier J, Cognat E, Hourrègue C, Munoz-Musat E, Decaix T, Hugon J, Estrada J, Sebbagh M, Bouaziz-Amar É, Lilamand M, Paquet C.

J Neurol. 2026 Mar 23;273(4):228. doi: 10.1007/s00415-026-13760-x.

Connecting the Dots: Neurobiological Interplay Between Type 2 Diabetes and Alzheimer's Disease

Foncea-Bitrán A, Barros-Osorio C, Arriaza F, Ramírez-López C, Ruiz LM, Barreto M, Ortiz FC, Cornejo F, Gómez GI.

Int J Mol Sci. 2026 Apr 2;27(7):3225. doi: 10.3390/ijms27073225.

Analytical Methods for Fluid Biomarkers in Alzheimer's Disease from Discovery to Clinical Implementation

Agnello L, Dominici R, Gambino CM, Scazzone C, Ciaccio M.

Int J Mol Sci. 2026 May 18;27(10):4518. doi: 10.3390/ijms27104518.

Should all MCI with Alzheimer's biological diagnosis receive anti-amyloid therapy?

Rossini PM, Pappalettera C.

Cell Death Dis. 2026 Feb 10;17(1):212. doi: 10.1038/s41419-026-08456-z.

Inflammatory markers associated with dementia: a systematic review and meta-analysis

Kuring JK, Mathias JL, Ward L, Tachas G.

J Psychiatr Res. 2026 Jun;197:26-40. doi: 10.1016/j.jpsychires.2026.02.044. Epub 2026 Feb 24.

Tau proteoforms as plasma biomarkers in Alzheimer's disease: mechanisms, measurement, and medicine

Kim E, Lee J, Han D.

Expert Rev Proteomics. 2026 Jan-Feb;23(1-2):1-11. doi: 10.1080/14789450.2025.2611853. Epub 2026 Jan 5.

Brain connectivity as a new target for Alzheimer's disease therapy?

Pini L, Allali G, Imbimbo BP, Germani M, Corbetta M.

Brain. 2026 Feb 7;149(2):432-438. doi: 10.1093/brain/awaf404.

A review of evidence supporting amyloid beta reduction as a surrogate endpoint in Alzheimer's disease

Chen T, Hutchison RM, Rubel C, Murphy J, Xie J, O'Gorman J, Dent G, Molenberghs G, Sormani MP, Hendrix S, Hansson O, Aisen P, Haeberlein SB, Tian Y.

J Prev Alzheimers Dis. 2026 Feb;13(2):100458. doi: 10.1016/j.tjpad.2025.100458. Epub 2026 Jan 1.

Programmed cell death: a promising management for Alzheimer's disease

Yang Q, Ren X, Jia R, Zheng L, Ou R, Xu Y, Luo Y, Yang G, Wang X.

Apoptosis. 2026 Mar 29;31(4):115. doi: 10.1007/s10495-026-02330-1.

Altered locus coeruleus links to atrophy and hypometabolism in individuals with high Alzheimer's disease biomarkers

Foyard E, Blanchard T, Landeau B, Chauveau L, Naveau M, Poisnel G, Bui E, Chetelat G, de Flores R; Medit‐Ageing Research Group.

Alzheimers Dement. 2026 Mar;22(3):e71212. doi: 10.1002/alz.71212.

The complement system in Alzheimer's disease: mechanisms, biomarkers, and therapeutic implications

Liu G, Deng B, Han X, Zhao Y, Zeng S, Yu S, Wang L, Wang S, Wu Y, Cai L, Wu Y, Yang H, Chen J.

Front Immunol. 2026 Apr 15;17:1798288. doi: 10.3389/fimmu.2026.1798288. eCollection 2026.

Are diagnostic technologies for alzheimer's disease and dementia cost-effective? A systematic review of economic evaluations

Kashem M, Haldenby O, Ahmad JF, Muhammad AA, Mostert CM, Ali S.

Alzheimers Res Ther. 2026 Jan 23;18(1):26. doi: 10.1186/s13195-025-01933-1.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias